Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06498973 | Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant | recruiting | Phase 1 | 43 | City of Hope Medical CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06533748 | Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma | recruiting | Phase 2 | 128 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07532525 | Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma | recruiting | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT00501826 | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | recruiting | Phase 2 | 160 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 276 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06928909 | Leukemia Adapted Protocol(LEAP) | recruiting | — | 30 | Baylor College of MedicineOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705178 | More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)(MaximALL) | recruiting | N/A | 180 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04659616 | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 1 | 32 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06289673 | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | recruiting | Phase 4 | 850 | St. Jude Children's Research HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06594445 | HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML | recruiting | Phase 1 | 45 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07133997 | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 26 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia(ALLight) | recruiting | Phase 1 / Phase 2 | 83 | AstraZenecaINDUSTRY | 9 | Jul 13, 2026 | clinicaltrials |
| NCT07228273 | Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia | recruiting | Phase 2 | 102 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21) | recruiting | Phase 3 | 160 | Princess Maxima Center for Pediatric OncologyOTHER | 24 | Jul 10, 2026 | clinicaltrials |
| NCT05442216 | Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents(TAGALONG) | recruiting | Phase 2 | 53 | Joshua ZeidnerOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06446661 | Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia | recruiting | N/A | 48 | University of ChicagoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695012 | CAR-T Cell Therapy for ALL(PAKCAR-ALL) | recruiting | Early Phase 1 | 10 | Dr. Zaineb AkramOTHER_GOV | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03810196 | CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT | recruiting | N/A | 50 | Children's Hospital of PhiladelphiaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07216443 | Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | recruiting | Phase 2 | 80 | Orca Biosystems, Inc.INDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07464951 | CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia(CART123) | recruiting | Phase 1 | 30 | Stephan Grupp MD PhDOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT01351545 | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | recruiting | — | 99,999 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06697600 | A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers(UR-GOAL RCT) | recruiting | N/A | 1,020 | University of RochesterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07019155 | Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants | recruiting | — | 510 | National Cancer Institute (NCI)NIH | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07325305 | Physical Activity and Exercise During Early Treatment Phases for Childhood Acute Lymphoblastic Leukaemia to Protect Against Muscle Loss and Improve Frailty Outcomes(PROTECT) | recruiting | N/A | 60 | Murdoch Childrens Research InstituteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07548983 | Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation | recruiting | Phase 1 | 40 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07684131 | EWALL-PH OBSERVARTORY 2022(Ewall Obs 2022) | recruiting | — | 100 | Versailles HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06234904 | Study of IBR733 Cell Injection in Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | Imbioray (Hangzhou) Biomedicine Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07304011 | Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent | recruiting | Phase 2 | 28 | University of California, DavisOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07680868 | Caris Chromoseq Data Collection | recruiting | — | 300 | Caris Science, Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04050280 | CLAG-GO for Patients With Persistent, Relapsed or Refractory AML | recruiting | Phase 2 | 39 | University of Maryland, BaltimoreOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04836507 | Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients | recruiting | Phase 1 / Phase 2 | 91 | Curocell Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06996119 | Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07292272 | Halt Aging in Survivors of Blood Cancers(HALTAging-1) | recruiting | N/A | 180 | University of NebraskaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677878 | Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL | recruiting | Phase 1 | 60 | Liping DouOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03932903 | Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia | recruiting | N/A | 60 | Northwestern UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06357182 | Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 1 | 30 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03571321 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 15 | University of ChicagoOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06802315 | Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)(BMT-13) | recruiting | Phase 2 | 38 | University of Illinois at ChicagoOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04869683 | Biocollection in MyeloDysplastic Syndrome (P-MDS)(P-MDS) | recruiting | N/A | 150 | University Hospital, BrestOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07575971 | Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 30 | Liping DouOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668557 | Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia(ICG415-AML-01) | recruiting | Phase 1 | 18 | iCell Gene TherapeuticsINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT06551584 | Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT | recruiting | Phase 1 | 24 | Stanford UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03128034 | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia | recruiting | Phase 1 / Phase 2 | 75 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2026source: clinicaltrials